Amneal Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amneal Pharmaceuticals, Inc.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.
Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.
After launching several high-value complex generic products in the last six months, Amneal aims to launch eight more complex generics by August 2021 to add “tremendous value” to its generics business.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.